Our Investigator Initiated Trial, POTENT, presented at #ELCC2025 by Dr Anna Minchom combines tepotinib + pembrolizumab to tackle immune resistance in NSCLC.
Promising early results prelude to expanding treatment options & improving outcomes for NSCLC patients.
#LungCancer #DDUIIT
2
0
0
0